Aptevo Therapeutics Inc. · NASDAQ:APVO
Aptevo Therapeutics — Investor Presentation (November 2017)
30 slides from Aptevo Therapeutics's investor presentation, Nov 2, 2017
Slide 1: Aptevo Therapeutics Investor Presentation
Aptevo Therapeutics Investor Presentation January 2017 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, product portfolio, product sales, capabilities and any other statements contai
Slide 3: Agenda
AGENDA Leadership in Bispecific Antibody Development Aptevo Today ADAPTIR – Differentiated Bispecific Platform Summary Advancing Aptevo Therapeutics
Slide 4: Aptevo: At a Glance
Aptevo: At a Glance Leading Oncology Platform Innovative ADAPTIR platform technology utilizing a promising approach in the highly attractive immuno-oncology field Leveraging Technology Targeted investments in bispecific ADAPTIR therapeutics Strong IP Estate Intend to own or exclusively license paten
Slide 5: Executive Leadership
Executive Leadership Senior Management Marvin White – President & CEO Former Emergent Director; Former CFO, St. Vincent’s Health; Former Exec. Director & CFO, Lilly USA Jeff Lamothe – SVP, CFO Former Emergent VP, Finance; Former CFO, Cangene Corporation Randy Maddux – SVP, Operations Former VP, Glob
Slide 6: Our Strategy
Our Strategy 1 2 3 Advance novel ADAPTIR product candidates, primarily in immuno-oncology Expand collaborations and partnerships Maximize cash flow from commercial portfolio to support R&D funding Innovating Aptevo Therapeutics
Slide 7: Product/Candidate Pipeline
Product/Candidate Technology Indication Pre-Clinical Clinical Development Stage Marketed Milestones/Highlights Phase I Phase II Phase III IXINITY Recombinant Protein Hemophilia B $1.0M WW in 2015 $7.0M (9/30/2016) WinRho Hyper Immune ITP $14.2M WW in 2015 $10.6M (9/30/2016) HepaGam B Hyper Immune HB
Slide 8: Commercial Portfolio – Hyperimmune Platform
Commercial Portfolio – Hyperimmune Platform US: [Rho (D) Immune Globulin Intravenous (Human)] Canada: (Rho(D) Immune Globulin (Human) for injection) Immune Thrombocytopenic Purpura (ITP) and suppression of Rhesus (Rh) isoimmunization US: [Hepatitis B Immune Globulin Intravenous (Human)] Canada: (Hep
Slide 9: Commercial Portfolio – Recombinant Platform
Commercial Portfolio – Recombinant Platform [coagulation factor IX (recombinant)] An intravenous recombinant human coagulation factor IX therapeutic for use in patients with Hemophilia B Strong growth opportunity WW rights owned by Aptevo U.S. launch mid-2015 Target market: Hemophilia B Young, activ
Slide 10: Agenda
AGENDA Leadership in Bispecific Antibody Development Aptevo Today ADAPTIR – Differentiated Bispecific Platform Summary Advancing Aptevo Therapeutics
Slide 11: ADAPTIR – A Differentiated Bispecific Antibody Platform Technology
MODULAR AND FLEXIBLE Monospecific and bispecific formats Flexible design supports reproducible generation of bispecifics with potent activity MULTIPLE MECHANISMS OF ACTION Redirected T-Cell Cytotoxicity (RTCC) Target receptors that stimulate or inhibit immunes responses Target cytokines to modify th
Slide 12: Expertise in Bispecific Antibodies Facilitates Rapid Development
Expertise in Bispecific Antibodies Facilitates Rapid Development from Concept to Clinic Protein Engineering Generate new binding domains or take partner’s mAbs and convert to ADAPTIR format Optimize for: Screening to reduce potential for immunogenicity Binding affinity Activity Expression Manufactur
Slide 13: ADAPTIR RTCC Mechanism of Action
ADAPTIR RTCC Mechanism of Action ADAPTIR Bispecific Molecules Mediate RTCC: Potent Immunotherapeutic for Cancer Tumor Antigen Bispecific molecule activates T cell to kill tumor cell CD3/TCR complex Target-dependent release of cytolytic granules from T cells kills tumor T cell expansion Death of tumo
Slide 14: ADAPTIR RTCC Key Advantages vs Other RTCC Bispecifics
ADAPTIR RTCC Therapeutics Key Advantages vs Other RTCC Bispecifics Antibody-like half-life obtained in preclinical studies; up to 12 days Potent target-dependent cytotoxicity in preclinical studies demonstrated for numerous tumor antigens Highly potent Low levels of cytokines produced after engageme
Slide 15: ADAPTIR RTCC Bispecifics Differentiated From Other Formats
ADAPTIR RTCC Bispecifics are Differentiated From Other Bispecific Formats Heterodimeric Bispecifics scFv A Fab A scFv B scFv B Fc A Fc B Fc A Fc B scFv A scFv B Fc Homodimeric ADAPTIR ADAPTIR™ RTCC molecules are more potent in preclinical studies compared to other bispecific platforms scFv–scFv Mono
Slide 16: ADAPTIR RTCC More Potent Than Heterodimer Format
ADAPTIR RTCC - More Potent than Bispecifics in Heterodimer Format Targeting the Same Antigen ADAPTIR Bispecifics Are More Potent Compared to Heterodimeric Antibody Formats Higher levels of maximal specific lysis of tumor cells Lower EC50 values Redirected T-cell Tumor Lysis assay using unstimulated
Slide 17: MOR209/ES414 More Potent Than BiTE
MOR209/ES414 - More Potent Than BiTE® (scFv-scFv Format)1 Assay utilizes MDA-PCa-2b target cells and primary T cells; 4 hr timepoint Protein EC50 MOR209/ES414 2.7 ± 0.6 pM scFv-scFv 99 ± 10 pM Concentration (pM) % Specific Lysis 0 5 10 15 20 25 1 10 100 1000 MOR209/ES414 (ADAPTIR molecule) αPSMA x α
Slide 18: ADAPTIR Clinical Pipeline
ADAPTIR Clinical Pipeline Product Candidate Technology Indication Pre-Clinical Clinical Development Stage Milestones Highlights Phase I Phase II Phase III Otlertuzumab ADAPTIR Monospecific CLL Executing Phase 1b combination study MOR209/ES414* ADAPTIR Bispecific RTCC mCRPC Immuno-oncology Executing
Slide 19: Clinical Candidate – otlertuzumab (CLL)
Clinical Candidate – otlertuzumab (CLL) aCD37 scFv Human IgG1 Fc Humanized monospecific protein therapeutic Targets CD37 and its signaling pathway involved in B-cell malignancies Built on ADAPTIR (modular protein therapeutic) platform Demonstrated anti-tumor activity Prolonged serum half-life (mouse
Slide 20: Otlertuzumab + Bendamustine Increased Overall Response Rate
Otlertuzumab + Bendamustine Significantly Increased Overall Response Rate Overall Response Complete Response Partial Response Stable Disease Progressive Disease Percent Response 100% 80% 60% 40% 20% 0% 69% 39% 59% 9% 3% 36% 16% 30% 16% 30% p = 0.026 Otlertuzumab and bendamustine (n=32) bendamustine
Slide 21: Otlertuzumab + Bendamustine Increased Progression Free Survival
5 month difference in PFS Otlertuzumab + Bendamustine Significantly Increased Progression Free Survival p = 0.019 0 5 10 15 20 25 0 20 40 60 80 100 Months Since Randomization Progression Free Survival (%) Otlertuzumab +Bendamustine Bendamustine Aptevo Therapeutics
Slide 22: Clinical Candidate – MOR209/ES414 (mCRPC)
Clinical Candidate – MOR209/ES414 (mCRPC) Anti-PSMA Anti-CD3 Humanized bispecific protein therapeutic Targets PSMA and CD3, a component of the T-cell receptor Demonstrated redirection of T-cells to kill tumor cells expressing PSMA in vitro and in vivo Prolonged serum half-life (mouse/NHP) vs antibod
Slide 23: MOR209/ES414 Delays Tumor Growth and Improves Survival
Delay of Tumor Growth Improved Overall Survival 0.3 mg MOR209/ES414* Vehicle 5 mg BiTE scFv-scFv* 3 mg MOR209/ES414* *P<0.01; †P<0.001 MOR209/ES414 was dosed on days 0, 4, 8; scFv-scFv molecule dosed daily on days 0-9 MOR209/ES414 Delays Tumor Growth and Improves Survival (Subcutaneous Xenograft Mod
Slide 24: ADAPTIR - Novel Preclinical Pipeline
ADAPTIR - Novel Preclinical Pipeline Molecule Target Antigen Type Target Indication(s) Development Activity Design in vitro RTCC in vivo POC Tox/IND Clinical: Phase 1 aROR1 x aCD3 Tyrosine Kinase (ROR1) Hematologic malignancies; solid tumors RTCC Candidate Undisclosed target Hematological malignanci
Slide 25: ADAPTIR RTCC Preclinical Candidate: ROR1
Targets hematologic malignancies and solid tumors Triple-negative breast cancer Ovarian cancer Non-small cell lung cancer Prostate cancer Kidney cancer CLL and MCL and subset of ALL (with t-1418 translocation) Ability to establish rapid clinical POC in heme-onc. Disease and simultaneously test in so
Slide 26: Agenda
AGENDA Leadership in Bispecific Antibody Development Aptevo Today ADAPTIR – Differentiated Bispecific Platform Summary Pioneering Aptevo Therapeutics
Slide 27: Financial Snapshot
Financial Snapshot Spin Date: August 1, 2016 Shares Outstanding 20.2M 9/30/2016 Cash Position $54M (approx.) $20M $15M 12/31/2016 Emergent Payment – 1/5/2017 MidCap Financial - 2nd tranche option 2015 Revenue $34M $28M $6M 2015 Pro Forma Total Product Sales Contracts, Grants, Collaborations 2016 Rev
Slide 28: Key Milestones – 18-24 Months
Key Milestones – 18-24 Months Development Complete Phase 1 study of MOR209/ES414; advance into Phase 2 development in partnership with MorphoSys Complete combination otlertuzumab/ibrutinib study Generate new ADAPTIR-based RTCC candidates Expand application of ADAPTIR-based candidates into new MOA Fi
Slide 29: Why Aptevo?
Why Aptevo? Solid financial position with runway into 2018 1 2 3 4 5 Established leadership and capabilities in protein-based therapies for cancer Proprietary, versatile, differentiated ADAPTIR technology platform Broad pipeline of clinical and preclinical development candidates Capital efficient mo
Slide 30: Aptevo Therapeutics
Aptevo Therapeutics Investor Presentation January 2017
Aptevo Therapeutics — Investor Presentation (November 2017) on 6ix